You are here

Funding

Duke CFAR Funding Opportunities

Dr. Gunn's Funding Newsletter - November 26, 2018

HIV Vaccine Research Grants for Medical Students
Seeking African American/Black and Latino/a medical students interested in HIV vaccine research

Please follow this link for more information!

 

2019 Adelante RFA

The NIH has opened the 2019 Adelante RFA. Adelante - meaning forward or onward in Spanish - embodies the primary mission of this mentored research program. Through Adelante, the Centers for AIDS Research strive to develop early-career investigators who focus on HIV/AIDS treatment, prevention, and care in the Latino/Hispanic community.

In this program, co-administered through the District of Columbia and Emory CFARs, the National Institutes of Health (NIH)-funded Centers for AIDS Research (CFARs) will support 2-year Adelante Team projects that include a 4 month Research Preparation period followed by a Research Implementation period of approximately 20 months. The goals of the program are to decrease HIV-related health disparities in the Hispanic/ Latino community and to promote the mentored development of new investigators to focus on HIV/AIDS in Hispanic/Latino populations.

Each CFAR Adelante Team will consist of a Principal Investigator (PI)/ Scholar, a CFAR Mentor, and a Collaborating Partner, who each meet the eligibility criteria.  Proposed research should be community based and reflect local Hispanic/Latino-community needs, as identified by science and the local community. Research proposal topics may include but are not limited to: 

  • Health disparities in the incidence of new HIV infections or in treatment outcomes of those living with HIV/AIDS.
  • Studies that examine factors that increase HIV risk in diverse Hispanic populations;
  • The cause of disparate outcomes of HIV infection and factors that influence pathogenesis in Hispanic populations;
  • Factors driving the social stigmatization of HIV in the Hispanic/Latino community;
  • Pilot interventions to engage faith-based organizations in the effective promotion of stigma reduction, HIV prevention promotion, HIV testing, timely linkage to HIV/AIDS care, and/or participation in research for experimental AIDS vaccines, biomedical prevention interventions, and treatment regimens;
  • Interventions to increase the frequency of HIV testing in Latino/Hispanic populations, timely linkage to care, earlier treatment initiation, better adherence to regimens, improved retention in care, and/or viral suppression;
  • Developing or testing novel, culturally-sensitive interventions for care coordination, particularly those that take a comprehensive approach to co-morbid medical and social service needs;
  • Behaviors after a negative HIV test (e.g., repeat HIV-testing, partner communication, use of PrEP or other prevention strategies), particularly in vulnerable and high risk Latino/Hispanic sub-populations such as drug users, sex workers, partners of HIV+ individuals, and young men who have sex with men;
  • Development and testing of culturally-responsive interventions to optimize repeat HIV testing, including interventions that reach individuals using technology (e.g., social media, messaging, applications on hand-held devices).

Applicants may request up to $75,000 (direct costs) per year, plus applicable indirect costs, not to exceed $150,000 in total costs per year. This funding may be used for salaries, technical support, laboratory supplies, equipment, enrollment in training classes or workshops, travel to the CFAR Mentor's institution, or other research or training-related activities.

You can find more details and the full RFA at the Adelante website here.

Additionally, we will be hosting an information webinar on Thursday, December 13th at 12 pm EST. Dial information is below and also available on the website.

Time: Dec 13, 2018 12:00 PM Eastern Time
Join Zoom Meeting: https://zoom.us/j/368789867
Dial by your location: +1 646 558 8656 US (New York)
Meeting ID: 368 789 867

 

Genetic Engineering Technologies for HIV Cure Research (U19 Clinical Trial Optional)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Mental Health (NIMH)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to apply genetic engineering technologies to HIV-1 cure research.  Gene- and/or cell-based approaches are sought that can achieve long-term remission of HIV-1 in the absence of antiretroviral treatment or complete elimination of HIV-1Applications are expected to include basic science/preclinical research as well as translational activities such as test-of-concept studies in animal models or human subjects and must be designed as collaborative efforts between academia and the private sector.
  • Open Date: February 11, 2019
  • Amount of Award: Application budgets are limited to $1.75 million in direct costs per year. Budgets should reflect the actual needs of the proposed project.
  • Due Date:March 11, 2019, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on this date.
    Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-18-058.html
  • End Date: March 12, 2019

 

High Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional)

 

Research on Comparative Effectiveness and Implementation of HIV/AIDS and Alcohol Interventions (R01 Clinical Trial Optional)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  • Purpose: HIV+ alcohol users remain at high risk for medication non-adherence and rapid disease progression, medication toxicities, organ failure, and poor viremic control, leading to increased risk of transmission and premature death. Recent advances in technology and biomedical science (e.g., new pharmacological agents, alcohol and inflammation biomarkers, internet and mobile technology) open new opportunities for strengthening the quality of HIV/alcohol-related implementation research through utilization of novel technology and biomarkers. This initiative seeks to advance knowledge on implementation and comparative effectiveness of alcohol-focused interventions among HIV+ individuals. Multiple factors need to be investigated, including potentially important patient and provider characteristics, and the organizational, financial, and structural factors that facilitate or inhibit the delivery of evidence-based services for HIV+ individuals with a range of severity of alcohol use problems. The overall goal is to inform clinical decision-making to implement effective interventions that will improve prevention, care, and outcomes across the continuum of HIV and alcohol problem severity and patterns of alcohol use. This solicitation is divided into two major topics. An application may choose to address one or both. These topics include: 1) comparative effectiveness research focused on understanding factors related to early detection, patient engagement and retention in appropriate alcohol and HIV care, and achieving and maintaining optimal treatment responses in diverse settings, and 2) modeling and testing alternative implementation approaches to improve uptake and scaling-up of effective interventions and reduce HIV disease transmission and progression.
  • Open Date: January 5, 2018
  • Amount of Award: NIH intends to fund an estimate of 4-6 awards, corresponding to a total of $3 million per year, for fiscal year 2018 to 2022.
  • Due Date: Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. 
    Standard AIDS dates apply), by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PAS-18-557.html
  • End Date: May 8, 2020

 

Detection of HIV for Self-Testing (R61/R33)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Mental Health (NIMH)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support bi-phasic developmental, discovery-driven, or hypothesis-driven research focused on innovative strategies to detect HIV either within the first two weeks of infection or to monitor viral rebound after stopping or developing resistance to antiretroviral therapy. Applications should propose simple diagnostic tools that would be feasible for a self-testing platform to allow untrained individuals to detect HIV. Interdisciplinary collaborations that include biomedical, physical, and behavioral sciences are highly encouraged.    
  • Open Date: November 6, 2017
  • Amount of Award: NIAID intends to commit $2,640,000 in FY 2018 to fund 3-6 awards. NIMH intends to commit $300,000 total cost in FY 2018.  Future year amounts will depend on annual appropriations. 
  • Due Date: December 6, 2017, December 6, 2018, and December 6, 2019 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
    December 6, 2017, December 6, 2018, and December 6, 2019, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PAR-17-471.html
  • End Date: December 7, 2019

 

Phylodynamic Tracking of HIV Transmission (R01)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support interdisciplinary research collaborations to study and optimize approaches using phylodynamic analyses of HIV genotyping databases to monitor HIV transmission networks in near real-time. The long-range goal is to leverage existing databases and support innovations in HIV phylodynamics to better inform testing, treatment, and prevention efforts. 
  • Open Date: February 15, 2017 
  • Amount of Award: NIH intends to fund an estimate of 4-7 awards, corresponding to a total of $4.39 M, for fiscal year 2018. Future year amounts will depend on annual appropriations.
  • Due Date: March 15, 2017; March 15, 2018; March 15, 2019  , by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates.
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PAR-17-048.html
  • End Date: March 16, 2019

 

"High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R01)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute of Dental and Craniofacial Research (NIDCR)
  • Purpose: The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals. 
    This FOA encourages high or medium priority AIDS research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection.
    This FOA encourages research efforts that will (i) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers and (ii) provide information on the clinical outcomes of such cancers in the HIV-infected population. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.   
  • Open Date: December 7, 2016
  • Amount of Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
  • Due Date: January 7, 2017
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PA-16-426.html
  • End Date: September 8, 2019

 

"High" or "Medium" Priority AIDS Research  on Non-AIDS-defining or AIDS-defining Cancers (R21)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute of Dental and Craniofacial Research (NIDCR)
  • Purpose: The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals.  
    This FOA encourages high or medium priority AIDS research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection. 
    This FOA encourages research efforts that will (i) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers and (ii) provide information on the clinical outcomes of such cancers in the HIV-infected population. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.   
  • Open Date: December 7, 2016
  • Amount of Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
  • Due Date: January 7, 2017
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PA-16-425.html
  • End Date: September 8, 2019

 

Apply now for the UCSF CAPS Visiting Professors Program

The UCSF Center for AIDS Prevention Studies (CAPS) has a Visiting Professors program to train investigators in conducting research with ethnic minority communities. The VP Program is designed to assist investigators already conducting HIV-prevention research with minority communities to improve their programs of research and obtain additional funding for their work. It includes a 6-week summer residency, pilot funding, and other mentorship and career development opportunities. More information is described below and at their website: http://vp.ucsf.edu/.